Menu
Menu
Newsletter
Menu
Newsletter
Intelligent Monitoring Group
Consumer General Industrials Mid Cap Stocks Retail Small Caps Stocks
Intelligent Monitoring Group (ASX:IMB): This >$200m All Ords company is Australasia’s largest independent security monitoring provider!
After a terrific FY24, FY25 was more difficult for Intelligent Monitoring Group (ASX:IMB) but it may have turned a corner. In FY24, this company (which we will call IMG to avoid confusion with the Illawarra-based mutual bank IMB) made >$40m EBITDA, went from being the 3rd largest company in its industry to the largest and set…
October 2, 20250Comments
EBR Systems
Biotech Stocks Healthcare Stocks Mid Cap Stocks
EBR Systems (ASX:EBR): Another heart-focused medtech that has gained FDA approval
Mere days after Artrya (ASX:AYA) obtained FDA approval for its heart-health technology, EBR Systems (ASX:EBR) has achieved that same feat. The company made a surprising 15% plunge on the day of the announcement, and the share price has been nuanced since. However, it is still a >$500m company more than when it first listed. Let's take…
October 1, 20250Comments
stocks that benefit from inflation
Blue Chip Stocks Consumer Energy Stocks
Which stocks that benefit from inflation the most? Here are 3 sectors to watch
Stocks that benefit from inflation do exist, but they might not be immediately obvious to find. After all, inflation can be a tricky economic phenomenon. It can have both beneficial and detrimental effects on various aspects of the economy, including investments. And even companies you think might benefit may not actually benefit from inflation. Stocks Down Under…
September 30, 20250Comments
Treasury Wine Estates
Blue Chip Stocks Consumer
Treasury Wine Estates (ASX:TWE): China’s 200% wine tariffs have been consigned to history, so is it now back to business as usual?
Poor Treasury Wine Estates (ASX:TWE) investors! After 3 and a half years of China's 200% tariffs on Australian wine imports, they were scrapped in March 2024. It was about this time we last wrote about the company and we posed the question: So is it now back to business as usual for one of Australia's…
September 29, 20250Comments
Promarker
Biotech Stocks Healthcare Stocks Life Sciences Small Caps Stocks Undervalued Stocks
Proteomics has launched 2 Promarker tests in a matter on months and is about to launch a 3rd
Proteomics' suite of Promarker tests are all being launched in 2025. The range includes: PromarkerD for DKD which has been launched in Australia and the USA; PromarkerEso for Esophageal cancer which is now commercially available in Australia, and PromarkerEndo for Endometriosis which will be commercialised shortly. Launching 3 tests in a a year is…
September 26, 20250Comments

the Kick-ass Multipurpose WordPress Theme

Investing in the Year of the Rat
2020, the Golden Year
Market trouble spots to avoid in 2020
© 2026 Kicker. All Rights Reserved.

Add Your Heading Text Here